Full Title
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid TumorsPurpose
The purpose of this study is to find the highest dose of the investigational immunotherapy drug REGN7075 that can be given alone and in combination with cemiplimab in people with inoperable or metastatic solid tumors. Patients will either receive REGN7075 alone followed by REGN7075 plus cemiplimab, or only combination treatment with REGN7075 plus cemiplimab. Both drugs are given intravenously (by vein).
REGN7075 is a bispecific antibody, which is designed to recognize and attach to two different proteins at the same time: one protein on the surface of cancer cells and one on the surface of immune system cells called T cells. REGN7075 targets the proteins EGFR on cancer cells and CD28 on T cells. Researchers think that REGN7075 may boost the immune system to fight cancer cells by activating T cells to destroy the tumor.
Cemiplimab takes the brakes off the immune response so the immune system can detect and destroy cancer cells. Its use with REGN7075 is considered investigational.